Affiliations 

  • 1 Centre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan, Malaysia
  • 2 Centre for Quality Management of Medicine, Faculty of Pharmacy, Universiti Kebangsaan, Malaysia
  • 3 Centre of Toxicology and Health Risk Study, Faculty of Health Sciences, Universiti Kebangsaan, Malaysia; and
  • 4 Department of Physiology, Faculty of Medicine, Universiti Kebangsaan, Malaysia
J Cardiovasc Pharmacol, 2022 Sep 01;80(3):393-406.
PMID: 35767710 DOI: 10.1097/FJC.0000000000001305

Abstract

Several types of cardiovascular cells use microRNA-21 ( miR-21 ), which has been linked to cardioprotection. In this study, we systematically reviewed the results of published papers on the therapeutic effect of miR-21 for myocardial infarction. Studies described the cardioprotective effects of miR-21 to reduce infarct size by improving angiogenesis, antiapoptotic, and anti-inflammatory mechanisms. Results suggest that cardioprotective effects of miR-21 may work synergistically to prevent the deterioration of cardiac function during postischemia. However, there are other results that indicate that miR-21 positively regulates tissue fibrosis, potentially worsening a postischemic injury. The dual functionalities of miR-21 occur through the targeting of genes and signaling pathways, such as PTEN , PDCD4 , KBTBD7 , NOS3 , STRN , and Spry-1 . This review provides insights into the future advancement of safe miR-21 -based genetic therapy in the treatment of myocardial infarction.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.